Genolution Inc is a Korea-based company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related to ribonucleic acid interference (RNAi) research. The Company is mainly engaged in the manufacture and sales of nucleic acid extraction reagents for extracting nucleic acids from human samples and automated nucleic acid extraction devices for automatically extracting nucleic acids from samples. The Company also provides RNAi services. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	₩1,304.00	-0.08%	8,636
23/07/26	₩1,305.00	+0.93%	19,052
22/07/26	₩1,293.00	+0.31%	17,688
21/07/26	₩1,289.00	-3.37%	45,748
20/07/26	₩1,334.00	-1.69%	45,906

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 24/07/2026			5-day change	1st Jan Change
1,304.00 ^KRW	-0.08%		-3.91%	-31.33%

02-19	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI

Market Cap	23.56B 16.13M 14.17M 13.18M 12.09M 22.72M 1.55B 23.07M 156M 61.13M 764M 60.56M 59.26M 2.64B	P/E 2024	-5.89x	P/E 2025	-2.95x
Enterprise Value	19.67B 13.47M 11.83M 11M 10.1M 18.97M 1.3B 19.26M 131M 51.05M 638M 50.57M 49.48M 2.21B	EV / Sales 2024	4.38x	EV / Sales 2025	3.23x
Free-Float	67.03%	Yield 2024 *	-	Yield 2025	-

02-19	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI
31/07/24	Genolution Inc. cancelled the transaction announced on May 7, 2024	CI
07/05/24	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd. and another investor	CI
09/01/24	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
09/01/24	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
09/01/24	Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	CI
13/10/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
10/07/23	Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	CI
10/07/23	Genolution Inc. authorizes a Buyback Plan.	CI
15/05/23	Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
05/04/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI
05/04/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI

1 day	-0.08%
1 week	-3.91%
Current month	+7.77%
1 month	+12.90%
3 months	-33.13%
6 months	-30.56%
Current year	-31.33%

Genolution Inc. Stock

Stocks

A225220

KR7225220003

Biotechnology & Medical Research

Valuation: Genolution Inc.

Chart: Genolution Inc.

Latest news : Genolution Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Genolution Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,251	1,380
1 month	1,005	1,415
Current year	957	2,120
1 year	957	2,830
3 years	957	5,140
5 years	957	9,381.19
10 years	957	13,118.81

Manager	Title	Age	Since
Min-Ee Kim CEO	Chief Executive Officer	40	-
Ki-Ok Kim CEO	Chief Executive Officer	71	01/02/2006
Sang-Hoon Kim DFI	Director of Finance/CFO	66	-

Director	Title	Age	Since
Hak-Soo Lee BRD	Director/Board Member	70	20/03/2020
Dong-Seon Kim BRD	Director/Board Member	71	28/03/2025
Ki-Ok Kim BRD	Director/Board Member	71	01/02/2006

Date	Insider	Type	Main position	Quantity	% Market Cap.
24/05/24	Sang-Hoon Kim	Others	Chief Financial Officer	404,000	2.1053%
19/05/24	Sang-Hoon Kim	Free	Chief Financial Officer	404,000	2.1053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOLUTION INC.	-0.08%	-3.91%	-40.18%	-69.71%	15.98M
VERACYTE, INC.	-2.19%	-4.41%	+133.83%	+98.08%	4.62B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-0.18%	+0.77%	+104.88%	+175.62%	3.57B
IOVANCE BIOTHERAPEUTICS, INC.	-2.73%	+7.08%	+25.69%	-34.94%	2.29B
BGI GENOMICS CO., LTD.	-0.90%	-4.02%	-28.84%	-37.05%	2.09B
CAREDX, INC.	-1.25%	-7.93%	+183.08%	+249.39%	1.94B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-4.11%	-4.65%	+158.02%	-45.92%	1.04B
SEEGENE, INC.	-0.54%	-4.03%	-8.51%	+27.44%	851M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-3.59%	-10.46%	-40.75%	-16.68%	497M
CURIOX BIOSYSTEMS CO., LTD	+4.02%	-5.71%	-0.77%	-	435M
Average	-1.14%	+0.59%	+48.64%	+38.47%	1.73B
Weighted average by Cap.	-1.48%	+0.36%	+85.47%	+81.20%

	2024	2025
Net sales	7.14B 4.89M 4.29M 3.99M 3.66M 6.88M 471M 6.99M 47.39M 18.52M 231M 18.34M 17.95M 800M	9.4B 6.44M 5.66M 5.26M 4.83M 9.07M 620M 9.21M 62.46M 24.4M 305M 24.17M 23.65M 1.05B
Net income	-6.83B -4.67M -4.11M -3.82M -3.5M -6.58M -450M -6.68M -45.33M -17.71M -221M -17.55M -17.17M -765M	-11.64B -7.97M -7M -6.51M -5.98M -11.23M -768M -11.4M -77.33M -30.21M -377M -29.93M -29.28M -1.31B
Net Debt	-8.95B -6.13M -5.38M -5.01M -4.59M -8.63M -590M -8.76M -59.44M -23.22M -290M -23.01M -22.51M -1B	-3.89B -2.66M -2.34M -2.17M -1.99M -3.75M -256M -3.8M -25.81M -10.08M -126M -9.99M -9.77M -436M